**Chapter 2**

*Amyloid Diseases*

NEJMoa1716153

[62] Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine. 2018;**379**:11-21. DOI: 10.1056/

Castleman's disease. Case Reports in Gastroenterology. 2013;**12**:476-481.

[70] Georgin-Lavialle S, Stankovic Stojanovic K, Buob D, et al. French amyloidosis CAPS study: AA

amyloidosis complicating cryopyrinassociated periodic syndrome: A study on 14 cases and review of 53 cases from literature. Pediatric Rheumatology Online Journal. 2015;**13**:32. DOI: 10.1186/1546-0096-13-S1-P32

[71] Sanz-Martín N, Samillán-Sosa Kdel R, De Miguel J, Martínez-Miguel P. Renal amyloidosis in leprosy, an infrequent cause of nephrotic syndrome

in Europe. BML Case Reports. 2016;**3**:bcr2016216038. DOI: 10.1136/

[72] Balwani MR, Kute VB, Shah PR, Wakhare P, Trivedi HL. Secondary renal amyloidosis in a patient of pulmonary tuberculosis and common variable immunodeficiency. Journal of Nephropharmacology. 2015;**4**:69-71

[73] Akçay S, Akman B, Ozdemir H, Eyüboğlu FO, Karacan O, Ozdemir N. Bronchiectasis-related amyloidosis as a cause of chronic renal failure. Renal

[74] Azzopardi JG, Lehner T. Systemic amyloidosis and malignant disease. Journal of Clinical Pathology.

[75] Gueutin V, Langlois AL, Shehwaro N, Elharraqui R, Rouvier P, Izzedine H. Nephrotic syndrome associated with lung Cancer: A rare case of malignancy associated with AA amyloidosis. Case Reports in Nephrology.

2013;**2013**:831903 10.1155/2013/831903

[76] Husby G, Marhaug G, Sletten K. Amyloid A in systemic amyloidosis associated with cancer. Clinical investigations. AACR.

1982;**42**:1600-1603

Failure. 2002;**24**:815-823

1966;**19**:539-548

bcr-2016-216038

DOI: 10.1159/000356825

[63] Millns H, Bergemann R,

phase 3 clinical trial with ISIS-TTRRx, a 2nd-generation antisense oligonucleotide targeting transthyretin (TTR), for the treatment of TTR amyloid cardiomyopathy. Orphanet Journal of Rare Diseases. 2015;**10**:8. DOI: 10.1186/1750-1172-10-S1-P8

Ackermann E, Monia B, Lukas MA. A

[64] Girnius S, Dember L, Doros G, Skinner M. The changing face of AA amyloidosis: A single center experience.

Amyloid. 2011;**18**:226-228. DOI: 10.3109/13506129.2011.574354085

[65] Simms RW, Prout MN, Cohen AS. The epidemiology of AL and AA amyloidosis. Baillière's Clinical Rheumatology. 1994;**8**:627-634. DOI: 10.1016/S0950-3579(05)80119-0

[66] Bunker D, Gorevic P. AA

10.1002/msj.21342

amyloidosis: Mount Sinai experience, 1997-2012. Mount Sinai Journal of Medicine. 2012;**79**:749-756. DOI:

[67] Oh YB, Bae SC, Jung JH, Kim TH, Jun JB, Jung SS, et al. Secondary renal amyloidosis in adult onset Still's disease: Case report and review of the literature. The Korean Journal of Internal Medicine. 2000;**15**:131-134. DOI: 10.3904/kjim.2000.15.2.131

[68] Harzallah A, El Jery HK, Hajji M, Mami I, Goucha R, Turki S, et al. Amyloïdosis complicating Behcet's disease. Open Journal of Clinical Diagnostics. 2016;**6**:42-46. DOI:

[69] Gaduputi V, Tariq H, Badipatla K, Ihimoyan A. Systemic reactive amyloidosis associated with

10.4236/ojcd.2016.63008

**20**
